The world is talking about ending AIDS. AVAC’s advocacy is dedicated to realizing that vision. To get there we must:
Findings from two trials on antibody-mediated prevention, the AMP Trials, are complex, and the implications for HIV prevention research are unfolding. So what does that mean for the field, and what other questions have been raised by these pioneering trials?
HIV Vaccine Awareness Day is just around the corner—May 18th! In preparation, AVAC invites you to mark your calendars and register for HIV Vaccines in the Midst of COVID, a webinar on Thursday, May 13 at 10 am EDT/ 1600 h Southern Africa/ 1700 h Eastern Africa.
We’ve updated our comprehensive primer on CAB-LA: Advocates’ Primer on Long-Acting Injectable Cabotegravir for PrEP: Understanding the Initial Results of HPTN 083 and HPTN 084, and held a May 3 webinar, where you can here from researchers and advocates.
The latest edition of Protecting Global Gains, Abiyamo Alayo: Happy Mother Radio Show Takes Community Outreach Further, describes how “mentor mothers” in Nigeria adapted to keep medicines and supplies flowing despite COVID-19 disruptions.
AVAC uses education, policy analysis, advocacy, community mobilization and a network of global collaborations to accelerate ethical development and global delivery of biomedical HIV prevention options. Read more
AVAC advocates for a comprehensive response to the epidemic, involving smart use of every proven HIV prevention option available today and sustained research into many new strategies.